Twice-yearly injections are 99% efficient at preventing HIV, according to a clinical study
A twice-yearly injection of Lenacapavir, however, offers a 96% lower risk of infection overall.
A twice-yearly injection of Lenacapavir, however, offers a 96% lower risk of infection overall.
A class of tumors known as soft tissue sarcoma of the extremities develops in the muscles, tendons, fat, blood vessels, or nerves of the arms and leg
Teri Boudreaux is thankful for the time she gets to spend with her family, whether it’s hiking, playing with her grandkids, travelling with her spouse, [Read More…]
The outcomes of an international Phase III clinical trial conducted by researchers from the University of Pennsylvania Perelman School of Medicine and a multicenter group [Read More…]
A novel vaccine candidate that offers protection against Lassa fever has been developed by researchers from Thomas Jefferson University and the University of Maryland Baltimore, [Read More…]
A Phase 1/2 trial included 15 individuals in total, among them three pediatric patients. The patients all suffered from the disease Leber congenital amaurosis caused by a gene that is essential in making proteins crucial to vision.
The rates of heart failure events and cardiovascular death were lower in the finerenone group compared with the placebo group.
Delivering a healthy copy of a gene to a person whose gene(s) are malfunctioning is known as gene therapy.